| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 119.998 | 200.104 | 239.468 | 240.300 | 239.759 | 239.995 | 239.040 | 240.173 | 240.310 | 240.278 |
| Total Income - EUR | 120.768 | 203.664 | 239.470 | 249.000 | 239.761 | 239.995 | 239.040 | 240.173 | 240.310 | 240.278 |
| Total Expenses - EUR | 132.699 | 137.473 | 122.230 | 126.264 | 106.511 | 107.240 | 103.317 | 110.089 | 132.635 | 162.131 |
| Gross Profit/Loss - EUR | -11.931 | 66.192 | 117.240 | 122.736 | 133.251 | 132.755 | 135.722 | 130.083 | 107.675 | 78.147 |
| Net Profit/Loss - EUR | -11.931 | 66.192 | 106.452 | 120.246 | 130.860 | 130.534 | 133.619 | 127.729 | 105.632 | 71.299 |
| Employees | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Check the financial reports for the company - Novogyn Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 907.939 | 915.307 | 844.287 | 772.719 | 719.494 | 668.292 | 615.960 | 595.941 | 572.974 | 546.952 |
| Current Assets | 26.803 | 9.530 | 1.233 | 608 | 1.535 | 7.557 | 56.841 | 42.597 | 89.287 | 124.022 |
| Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 14.710 | 2.266 | 783 | 381 | 381 | 260 | 1.611 | 4.526 | 7.555 | 2.441 |
| Cash | 12.094 | 7.264 | 451 | 227 | 1.153 | 7.297 | 55.230 | 38.071 | 81.732 | 121.581 |
| Shareholders Funds | -166.390 | -98.502 | 10.170 | 130.229 | 258.567 | 384.199 | 509.298 | 382.467 | 486.939 | 414.794 |
| Social Capital | 90 | 89 | 88 | 86 | 84 | 83 | 81 | 81 | 81 | 80 |
| Debts | 1.101.443 | 1.023.739 | 835.754 | 643.495 | 462.767 | 292.013 | 163.806 | 256.409 | 208.279 | 256.578 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "6820 - 6820" | |||||||||
| CAEN Financial Year |
6820
|
|||||||||
Comments - Novogyn Srl